Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (Annals of Hematology, (2021), 100, 5, (1181-1194), 10.1007/s00277-021-04465-4)

Michael Heuser, B. Douglas Smith, Walter Fiedler, Mikkael A. Sekeres, Pau Montesinos, Brian Leber, Akil Merchant, Cristina Papayannidis, José A. Pérez-Simón, Caroline J. Hoang, Thomas O’Brien, Weidong Wendy Ma, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jorge E. Cortes

Research output: Contribution to journalComment/debatepeer-review

Abstract

Due to an oversight during the preparation of figures for manuscript submission, the numbers of patients at risk were omitted from the bottom of Fig. 1, panel C. These have now been added along the x-axis to ensure that readers have the most complete information regarding the analysis shown. The original article has been corrected.

Original languageEnglish (US)
JournalAnnals of Hematology
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (Annals of Hematology, (2021), 100, 5, (1181-1194), 10.1007/s00277-021-04465-4)'. Together they form a unique fingerprint.

Cite this